The Latest Breaking News from Novo Nordisk

Three cases of suicidal and self-harm thoughts identified in Iceland, regulator says

“We're experiencing something here that is very, very different, very exciting from a healthcare perspective, and very expensive,” says Aon's Michael Manolakis.

A few years ago, celebrity weight-control practices were out of most people’s reach. Live-in chefs and personal trainers, not to mention elaborate surgical procedures like the Brazilian butt lift, were not real options for most. But with the advent of drugs such as semaglutide, it seems that anyone can go…

As Wegovy is set to be available on prescription in the UK, we asked doctors what they think of the controversial weight loss injections

The pharmaceutical sector performs relatively well during economic uncertainties due to inelastic demand for its products and services. While prominent players Tilray Brands (TLRY) and Novo Nordisk (NVO) should benefit, which stock is the better buy now? Read more to find out.

The tennis champion shared her decision to take this step was multi-faceted and motivated by a desire to "be at a healthy place."

The National Institute for Health and Care Excellence gave approval for the use of appetite suppressant Wegovy (semaglutide) earlier this year - here are more details about it

Ministers have announced plans which could see tens of thousands given access to new weight-loss drug

Novo Nordisk is already the global kingpin in diabetes treatments, with about 30% of the $50+ billion global diabetes market and around half of the $20 billion insulin therapy market. Now, it is becoming a powerhouse in weight-loss drugs, thanks to its Wegovy drug.